IN2014DN11099A - - Google Patents

Info

Publication number
IN2014DN11099A
IN2014DN11099A IN11099DEN2014A IN2014DN11099A IN 2014DN11099 A IN2014DN11099 A IN 2014DN11099A IN 11099DEN2014 A IN11099DEN2014 A IN 11099DEN2014A IN 2014DN11099 A IN2014DN11099 A IN 2014DN11099A
Authority
IN
India
Prior art keywords
liposomal irinotecan
leucovorin
fluorouracil
administered
patient
Prior art date
Application number
Inventor
Eliel Bayever
Navreet Dhindsa
Jonathan Basil Fitzgerald
Peter Laivins
Victor Moyo
Clet Niyikiza
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48692681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN11099(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of IN2014DN11099A publication Critical patent/IN2014DN11099A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM 398) alone or in combination with additional therapeutic agents. In one embodiment the liposomal irinotecan (MM 398) is co administered with 5 fluorouracil and leucovorin.
IN11099DEN2014 2012-06-13 2013-06-12 IN2014DN11099A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261659211P 2012-06-13 2012-06-13
US201361784382P 2013-03-14 2013-03-14
PCT/US2013/045495 WO2013188586A1 (en) 2012-06-13 2013-06-12 Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan

Publications (1)

Publication Number Publication Date
IN2014DN11099A true IN2014DN11099A (en) 2015-09-25

Family

ID=48692681

Family Applications (1)

Application Number Title Priority Date Filing Date
IN11099DEN2014 IN2014DN11099A (en) 2012-06-13 2013-06-12

Country Status (26)

Country Link
US (10) US9452162B2 (en)
EP (4) EP3919048B1 (en)
JP (3) JP6310911B2 (en)
KR (3) KR101776808B1 (en)
CN (2) CN110051631A (en)
AU (3) AU2013202947B2 (en)
BR (1) BR112014031088A8 (en)
CA (1) CA2875824C (en)
DK (3) DK2861210T3 (en)
ES (2) ES2880089T3 (en)
FI (1) FI3919048T3 (en)
HR (1) HRP20260159T1 (en)
IL (3) IL294886A (en)
IN (1) IN2014DN11099A (en)
LT (1) LT3919048T (en)
MX (1) MX376937B (en)
NZ (1) NZ702469A (en)
PL (3) PL3266456T3 (en)
PT (3) PT3919048T (en)
RS (1) RS67811B1 (en)
RU (1) RU2663450C2 (en)
SI (3) SI2861210T1 (en)
SM (1) SMT202600126T1 (en)
TW (3) TWI729492B (en)
WO (1) WO2013188586A1 (en)
ZA (1) ZA201408804B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101462825B1 (en) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 Liposomes useful for drug delivery
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
AU2015206667B2 (en) 2014-01-14 2020-05-14 Nektar Therapeutics Combination-based treatment method
MA39599A (en) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage and administration anti-egfr therapeutics
AU2015360761B2 (en) * 2014-12-09 2021-05-20 Ipsen Biopharm Ltd. Treatment of breast cancer with liposomal irinotecan
TW201701880A (en) * 2015-04-14 2017-01-16 莫瑞麥克製藥公司 Methods for improving the pharmacokinetics and therapeutic index of sustained release drug therapies
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
SG10201913073YA (en) 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
EP3791876A1 (en) * 2015-08-21 2021-03-17 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
JP2018527377A (en) * 2015-09-16 2018-09-20 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Combining Topoisomerase-I Inhibitors with Immunotherapy in the Treatment of Cancer - Patent application
ES3036518T3 (en) 2015-10-16 2025-09-19 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
WO2017172678A1 (en) * 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
AU2017267449A1 (en) * 2016-05-18 2018-11-15 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
RU2761953C2 (en) * 2016-11-02 2021-12-14 Ипсен Биофарм Лтд. Treatment of stomach cancer using combination types of therapy containing liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)
WO2020079692A1 (en) 2018-10-17 2020-04-23 Biolinerx Ltd. Treatment of metastatic pancreatic adenocarcinoma
WO2020148744A1 (en) * 2019-01-17 2020-07-23 Biolinerx Ltd. Combination therapy for treatment of pancreatic cancer
EP3911353A1 (en) * 2019-01-17 2021-11-24 BioLineRx Ltd. Specific combination therapy for treatment of pancreatic cancer
EP4087545A1 (en) 2020-01-10 2022-11-16 R-Pharm US Operating LLC Compositions of ixabepilone
EP4087535A1 (en) 2020-01-10 2022-11-16 Tyndall Formulation Services, LLC Formulations of sn-38 with poly(amino acid) block polymers
US11286344B2 (en) 2020-01-10 2022-03-29 Tyndall Formulation Services, LLC Polymer excipients for drug delivery applications
AU2022357570A1 (en) * 2021-10-03 2024-04-11 Systimmune, Inc. Methods of treating cancer and the pharmaceutical compositions thereof

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2628659A (en) * 1951-01-17 1953-02-17 Charles R Carpenter Convertible furniture article
JPS6019790A (en) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd Novel camptothecin derivative
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
JPH0720857B2 (en) 1988-08-11 1995-03-08 テルモ株式会社 Liposome and its manufacturing method
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5538954A (en) 1994-06-24 1996-07-23 A/S Dumex (Dumex Ltd.) Salts of tetracyclines
US5783568A (en) 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
DE19605024A1 (en) 1996-01-31 1997-08-07 Schering Ag New selective taxanes, processes for their preparation and their pharmaceutical use
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
WO1998017256A1 (en) 1996-10-22 1998-04-30 Dmitri Kirpotin Compound-loaded liposomes and methods for their preparation
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
CA2346879A1 (en) 1998-09-16 2000-04-27 Alza Corporation Liposome-entrapped topoisomerase inhibitors
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
AU4564200A (en) 1999-04-29 2000-11-17 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
ATE341310T1 (en) 2000-02-04 2006-10-15 Lipoxen Technologies Ltd DEHYDRATION/REHYDRATION PROCESS FOR PRODUCING LIPOSOMES
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
JP4679028B2 (en) 2000-05-15 2011-04-27 セルジーン コーポレイション Compositions and methods for treating colorectal cancer
EP1299085B1 (en) 2000-06-30 2005-11-16 Inex Pharmaceuticals Corp. Improved liposomal camptothecins and uses thereof
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
HUP0303616A3 (en) 2001-03-26 2006-07-28 Alza Corp Mountain View Liposome composition for improved intracellular delivery of a therapeutic agent
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
JP2005501840A (en) 2001-07-23 2005-01-20 エピダウロス・バイオテクノロジー・アクチェンゲゼルシャフト Means and methods for improved treatment of cancer
US20030077833A1 (en) * 2001-09-07 2003-04-24 Queen's University At Kingston Diagnositc methods for determining susceptibility to convulsive conditions
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
ITBO20010610A1 (en) 2001-10-05 2003-04-05 Haworth S P A DEVICE FOR THE CONNECTION OF LEGS TO FURNISHING ELEMENTS, AND FURNISHING ELEMENT INCLUDING SUCH DEVICE
CA2752143C (en) 2002-05-15 2014-09-23 Sutter West Bay Hospitals Delivery of nucleic acid-like compounds
CA2487425A1 (en) 2002-05-31 2003-12-11 Transmolecular, Inc. Combination chemotherapy with chlorotoxin
AU2003296897A1 (en) 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
RS20150135A1 (en) 2003-05-30 2015-08-31 Genentech Inc. TREATMENT WITH ANTI-VEGF ANTIBODIES
KR101462825B1 (en) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 Liposomes useful for drug delivery
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
NZ551748A (en) 2004-06-01 2010-02-26 Yakult Honsha Kk Irinotecan formulation
RU2006146625A (en) 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) TREATMENT WITH IRINOTEKAN (SRT-11) AND AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR (EGFR)
JP2006248978A (en) 2005-03-10 2006-09-21 Mebiopharm Co Ltd New liposome preparation
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
EP1951239A2 (en) 2005-10-25 2008-08-06 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
EP1954286A2 (en) * 2005-11-10 2008-08-13 SmithKline Beecham Corporation Inhibitors of akt activity
US20090148506A1 (en) * 2005-12-22 2009-06-11 Awa Dicko Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
SI2338487T1 (en) 2006-01-17 2014-01-31 Abbott Laboratories Combination therapy with PARP inhibitors
EP2004175A4 (en) 2006-03-16 2010-12-15 Bionumerik Pharmaceuticals Inc Anti-cancer activity augmentation compounds and formulations and methods of use thereof
KR101153058B1 (en) * 2006-11-30 2012-06-04 아크레이 가부시키가이샤 Primer set for amplification of ugt1a1 gene, reagent for amplification of ugt1a1 gene comprising the same, and use of the same
NZ579644A (en) 2007-02-16 2012-05-25 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
US20120003160A1 (en) 2007-06-29 2012-01-05 Amag Pharmaceuticals, Inc. Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session
WO2009097011A1 (en) 2007-08-17 2009-08-06 Celator Pharmaceuticals, Inc. Improved platinum drug formulations
CN101878229A (en) * 2007-09-28 2010-11-03 巴塞尔大学医院 Immunoliposomes for the treatment of cancer
AU2008321382A1 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents
AU2008333786A1 (en) 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and PARP inhibitors
TWI444384B (en) * 2008-02-20 2014-07-11 Gilead Sciences Inc Nucleotide analogues and their use in the treatment of malignancies
MX2010010480A (en) 2008-03-25 2010-10-15 Schering Corp Methods for treating or preventing colorectal cancer.
US8067432B2 (en) 2008-03-31 2011-11-29 University Of Kentucky Research Foundation Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
JP5639039B2 (en) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド Human serum albumin linker and its conjugates
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
EP2341908B1 (en) 2008-09-26 2016-04-13 Institut de Cancérologie de l'Ouest (I.C.O) Individual 5-fluorouracile dose optimization in folfiri treatment
CN102282168A (en) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 Human serum albumin linker and its conjugate
WO2010125462A2 (en) 2009-05-01 2010-11-04 Oncozyme Pharma Inc. Pentamidine combinations for treating cancer
PT2508170E (en) 2009-12-03 2015-10-16 Shanghai Hengrui Pharm Co Ltd Liposome of irinotecan or its hydrochloride and preparation method thereof
KR20130088116A (en) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 Methods of treatment of pancreatic cancer
WO2012012454A1 (en) 2010-07-19 2012-01-26 Bipar Sciences, Inc. Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan
KR20130048242A (en) 2010-07-22 2013-05-09 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Anti-tumor antigen antibodies and methods of use
WO2012031293A1 (en) 2010-09-03 2012-03-08 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of cancer
WO2012078695A2 (en) 2010-12-06 2012-06-14 Merrimack Pharmaceuticals, Inc. Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents
JP5947807B2 (en) 2010-12-14 2016-07-06 テクニカル ユニバーシティ オブ デンマークＴｅｃｈｎｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｄｅｎｍａｒｋ Encapsulation of radionuclides in nanoparticle compositions
AU2012217685B2 (en) 2011-02-15 2017-05-18 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
MX336197B (en) 2011-04-19 2016-01-11 Merrimack Pharmaceuticals Inc Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies.
JO3283B1 (en) * 2011-04-26 2018-09-16 Sanofi Sa Composition including Afflipersept, Folinic Acid, 5- Fluorouracil (5- Fu) and Irenosetan (FOLFIRI)
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2013138371A1 (en) * 2012-03-12 2013-09-19 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody
WO2013158803A1 (en) 2012-04-17 2013-10-24 Merrimack Pharmaceuticals, Inc. Compositions and methods for non-invasive imaging
AU2013202947B2 (en) * 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
WO2014113167A1 (en) 2012-12-14 2014-07-24 Merrimack Pharmaceuticals, Inc. Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents
US9616081B2 (en) 2013-03-27 2017-04-11 Taiho Pharmaceutical Co., Ltd. Antitumor agent including low-dose irinotecan hydrochloride hydrate
US10111871B2 (en) 2013-08-27 2018-10-30 Northeastern University Nanoparticle drug delivery system and method of treating cancer and neurotrauma
WO2015061592A1 (en) 2013-10-23 2015-04-30 Merrimack Pharmaceuticals, Inc. Liposomes for non-invasive imaging and drug delivery
AU2015360761B2 (en) 2014-12-09 2021-05-20 Ipsen Biopharm Ltd. Treatment of breast cancer with liposomal irinotecan
TW201701880A (en) 2015-04-14 2017-01-16 莫瑞麥克製藥公司 Methods for improving the pharmacokinetics and therapeutic index of sustained release drug therapies
SG10201913073YA (en) 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
EP3791876A1 (en) 2015-08-21 2021-03-17 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
ES3036518T3 (en) 2015-10-16 2025-09-19 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
US20170202840A1 (en) 2016-01-14 2017-07-20 Merrimack Pharmaceuticals, Inc. Treatment of pancreatic cancer with liposomal irinotecan
WO2017172678A1 (en) 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
AU2017267449A1 (en) 2016-05-18 2018-11-15 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
US20170333421A1 (en) 2016-05-18 2017-11-23 Ipsen Biopharm Ltd. Population Pharmacokinetics of Liposomal Irinotecan
RU2761953C2 (en) 2016-11-02 2021-12-14 Ипсен Биофарм Лтд. Treatment of stomach cancer using combination types of therapy containing liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)

Also Published As

Publication number Publication date
SI3919048T1 (en) 2026-04-30
US20190117643A1 (en) 2019-04-25
AU2018201942A1 (en) 2018-04-12
AU2013202947A1 (en) 2014-01-16
SI3266456T1 (en) 2022-03-31
JP2015523355A (en) 2015-08-13
RS67811B1 (en) 2026-03-31
IL235937A0 (en) 2015-01-29
IL235937B (en) 2022-08-01
TW201831168A (en) 2018-09-01
JP2017149783A (en) 2017-08-31
CN110051631A (en) 2019-07-26
HK1248608A1 (en) 2018-10-19
KR20190107010A (en) 2019-09-18
ES2880089T3 (en) 2021-11-23
PL2861210T3 (en) 2017-12-29
DK3266456T3 (en) 2021-07-05
PL3266456T3 (en) 2021-11-29
RU2018126616A (en) 2019-03-12
PT3266456T (en) 2021-07-28
EP2861210A1 (en) 2015-04-22
JP6857210B2 (en) 2021-04-14
SI2861210T1 (en) 2017-10-30
AU2018201942B2 (en) 2019-12-05
EP3266456B1 (en) 2021-05-05
EP4741019A2 (en) 2026-05-13
CA2875824C (en) 2021-05-18
RU2663450C2 (en) 2018-08-06
US10980795B2 (en) 2021-04-20
FI3919048T3 (en) 2026-03-13
BR112014031088A8 (en) 2021-06-22
EP3919048B1 (en) 2026-01-28
EP3266456A1 (en) 2018-01-10
IL294886A (en) 2022-09-01
WO2013188586A1 (en) 2013-12-19
TWI729492B (en) 2021-06-01
AU2013202947B2 (en) 2016-06-02
MX2014015391A (en) 2015-06-17
US20150328156A1 (en) 2015-11-19
TWI630924B (en) 2018-08-01
TW202027727A (en) 2020-08-01
US20170065578A1 (en) 2017-03-09
HK1209627A1 (en) 2016-04-08
US20160074382A1 (en) 2016-03-17
US20150374682A1 (en) 2015-12-31
RU2015100529A (en) 2016-08-10
BR112014031088A2 (en) 2017-06-27
JP2019116517A (en) 2019-07-18
EP2861210B1 (en) 2017-05-03
NZ702469A (en) 2017-08-25
AU2013274287A1 (en) 2015-01-29
PT2861210T (en) 2017-07-26
AU2013274287B2 (en) 2017-12-21
ZA201408804B (en) 2017-06-28
MX376937B (en) 2025-03-07
US9339497B2 (en) 2016-05-17
US20170368056A1 (en) 2017-12-28
EP4741019A3 (en) 2026-07-22
HRP20260159T1 (en) 2026-03-27
KR20150021565A (en) 2015-03-02
KR20170104638A (en) 2017-09-15
EP3919048A1 (en) 2021-12-08
LT3919048T (en) 2026-03-25
US9452162B2 (en) 2016-09-27
US20160228428A1 (en) 2016-08-11
CN104717961A (en) 2015-06-17
US20150182521A1 (en) 2015-07-02
KR101776808B1 (en) 2017-09-11
CA2875824A1 (en) 2013-12-19
ES2632915T3 (en) 2017-09-18
DK3919048T3 (en) 2026-02-09
TW201412345A (en) 2014-04-01
US20220096458A1 (en) 2022-03-31
PL3919048T3 (en) 2026-05-18
IL304631A (en) 2023-09-01
PT3919048T (en) 2026-04-14
DK2861210T3 (en) 2017-07-24
SMT202600126T1 (en) 2026-05-12
US20240226090A1 (en) 2024-07-11
JP6310911B2 (en) 2018-04-11
US9364473B2 (en) 2016-06-14
KR101997206B1 (en) 2019-07-08
US9492442B2 (en) 2016-11-15

Similar Documents

Publication Publication Date Title
AU2018201942B2 (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
MX2017014338A (en) Targeted selection of patients for treatment with cortistatin derivatives.
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
PH12017501500A1 (en) Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
NZ631144A (en) Compositions and methods for transmucosal absorption
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
NZ711373A (en) Fragments of p97 and uses thereof
MY204500A (en) Dosing regimen associated with long acting injectable paliperidone esters
SG10201903112WA (en) Treatment of cancer using coenzyme q10 combination therapies
IN2015DN03219A (en)
GB201111485D0 (en) Drug composition and its use in therapy
PH12014502738A1 (en) High-xten fusion protein and its use in the treatment of growth hormone deficiency
PH12014500386A1 (en) Combination treatment for hepatitis c
SG195110A1 (en) Pirfenidone and anti-fibrotic therapy in selected patients
MX2015010791A (en) Methods of treating cancer and preventing drug resistance.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
HK1201462A1 (en) Methods of treating cancer
IN2014MN02214A (en)
MX2015012899A (en) Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors.
PH12014500381A1 (en) Therapeutic methods
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
NZ594414A (en) Fused amino pyridines for the treatment of brain tumors
HK1200731A1 (en) Diethyl- [6- (4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl) - naphthalen-2-yl-methyl] -ammonium chloride for use in the treatment of muscular dystrophy
EP2836217A4 (en) Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor